Get started
Work

MA09.09 Long-Term Outcomes to Tepotinib Plus Gefitinib in Patients with EGFR-Mutant NSCLC and MET Dysregulation: 18-Month Follow-Up

Year: 2019
Type: conference-abstract
DOI: 10.1016/j.jtho.2019.08.571
Authors: Y. Wu, Y. Cheng, J. Zhou, S. Lu, Y. Zhang, J. Zhao, D. Kim, R. Soo, S. Kim, H. Pan, Y. Chen, C. Chian, X. Liu, D. Tan, R. Bruns, J. Straub, A. Johne, J. Scheele, K. Park, J.C. Yang
Institutions: Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Jilin Province Tumor Hospital, First Affiliated Hospital Zhejiang University, Shanghai Chest Hospital, Zhejiang Cancer Hospital, Peking University Cancer Hospital, Seoul National University Hospital, National University Cancer Institute, Singapore, Asan Medical Center, Sir Run Run Shaw Hospital, Taipei Veterans General Hospital, Tri-Service General Hospital, National Defense Medical Center, Academy of Military Medical Sciences, National Cancer Centre Singapore, Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), Samsung Medical Center, Sungkyunkwan University, National Taiwan University Hospital
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2981609990
Cites:
Cited by: 8
Related to: 10